Key result
Mitral valve plasty was associated with lower early mortality and improved long-term survival compared to mitral valve replacement in patients with infectious endocarditis.
Why the study?
While mitral valve plasty shows better clinical outcomes than replacement in degenerative disease, its advantages in patients with infectious endocarditis remain unclear.
Does surgical mitral valve plasty improve clinical outcomes compared to mitral valve replacement in patients with infectious endocarditis?
Meta-Analysis (n=25,615)
Does surgical mitral valve plasty improve clinical outcomes compared to mitral valve replacement in patients with infectious endocarditis?
In patients with infectious endocarditis, mitral valve plasty is associated with lower early and long-term mortality compared to mitral valve replacement, though it may carry a higher risk of reoperation.
Answers are grounded in this paper and cite their sources.
Supports preferring mitral valve plasty in infectious endocarditis when feasible; extends observational data but leaves randomized confirmation open.
Background: For degenerative mitral disease, more and more evidences support that mitral valve plasty (MVP) has much better clincial outcomes than mitral valve replacement (MVR). However, the advantages of MVP in patients suffering from infectious endocarditis (IE) are unclear. To evaluate the appropriateness of MVP in IE patients, we conducted this meta-analysis. Based on the difference between active and healed phase, we not only compared the result of patients with IE, but also identified the subgroup with active IE. Methods: We systematically searched the clinical trials comparing clinical outcomes of MVP and MVR in patients suffering from IE. Relevant articles were searched from January 1, 2000 to March 18, 2021 in Pubmed and Cochrane Library. Studies were excluded if they were with Newcastle-Ottawa Scale (NOS) score less than 6 or lacking of direct comparisons between MVP and MVR. Results: 23 studies were involved and 25,615 patients were included. Pooled analysis showed fewer adverse events and early or long-term death in the MVP group. However, more reoperations existed in this patient group. And the reinfection rate was close between two groups. Similar results were observed after identifying active IE subgroup, but there is no difference in the freedom from reoperation due to all-events. Conclusions: Although limitimations exited in this study, patients suffering from IE can benefit from both MVP and MVR. For surgeons with consummate skills, MVP can be the preferred choice for suitable IE patients.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) conducted a meta-analysis in infectious endocarditis (n=25,615). Mitral valve plasty vs. Mitral valve replacement was evaluated on Early mortality (OR 0.45, 95% CI 0.33-0.61). Mitral valve plasty was associated with lower early mortality and improved long-term survival compared to mitral valve replacement in patients with infectious endocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: